Monomeric or Homodimer Conjugates of Fibroblast Activation Protein Inhibitor and Cyanine 7 Bearing a Meso-Chloride as Near-Infrared Fluorescence Probes: Design, Synthesis, and Comparative In Vivo Imaging of Distinct Breast Cancer Subtypes
Panpan Chen, Zhipeng Lu, Xiaowei Feng, Yan Hu, Yajuan Qin, Yaping Lu, Feng Han, Tingyou Li
{"title":"Monomeric or Homodimer Conjugates of Fibroblast Activation Protein Inhibitor and Cyanine 7 Bearing a Meso-Chloride as Near-Infrared Fluorescence Probes: Design, Synthesis, and Comparative In Vivo Imaging of Distinct Breast Cancer Subtypes","authors":"Panpan Chen, Zhipeng Lu, Xiaowei Feng, Yan Hu, Yajuan Qin, Yaping Lu, Feng Han, Tingyou Li","doi":"10.1021/acs.jmedchem.4c01968","DOIUrl":null,"url":null,"abstract":"Intraoperative fluorescence navigation can illuminate the tumor, directing surgeons to accurately achieve negative margins, which not only reduces recurrence but also minimizes the incidence of complications. Herein, we developed two near-infrared fluorescent probes <b>FAPI-Cy7-Cl</b> (Em<sub>max</sub> = 820 nm) and <b>(FAPI)</b><sub><b>2</b></sub><b>-Cy7-Cl</b> (Em<sub>max</sub> = 823 nm) with prolonged tumor retention (>72 h) and high target-to-background ratios (up to 4.5) based on the conjugation of pan-cancer targeted fibroblast activation protein inhibitor (FAPI) and the “tumor-seeking” Cyanine 7 bearing a meso-chloride and a cyclohexenyl skeleton (Cy7-Cl). Specifically, <b>FAPI-Cy7-Cl</b> exhibited superior imaging performance in both estrogen receptor α positive breast cancer (MCF-7) and triple-negative breast cancer (TNBC) (MDA-MB-231) subtypes in mouse models. Notably, in the MDA-MB-231 tumor-bearing model, the tumor-to-liver ratio (T/L) of <b>FAPI-Cy7-Cl</b> increased rapidly after 2 h postinjection, reaching nearly 4.5 at 48 h, making it an optimal imaging probe for guiding TNBC surgery resection.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"11 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01968","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Intraoperative fluorescence navigation can illuminate the tumor, directing surgeons to accurately achieve negative margins, which not only reduces recurrence but also minimizes the incidence of complications. Herein, we developed two near-infrared fluorescent probes FAPI-Cy7-Cl (Emmax = 820 nm) and (FAPI)2-Cy7-Cl (Emmax = 823 nm) with prolonged tumor retention (>72 h) and high target-to-background ratios (up to 4.5) based on the conjugation of pan-cancer targeted fibroblast activation protein inhibitor (FAPI) and the “tumor-seeking” Cyanine 7 bearing a meso-chloride and a cyclohexenyl skeleton (Cy7-Cl). Specifically, FAPI-Cy7-Cl exhibited superior imaging performance in both estrogen receptor α positive breast cancer (MCF-7) and triple-negative breast cancer (TNBC) (MDA-MB-231) subtypes in mouse models. Notably, in the MDA-MB-231 tumor-bearing model, the tumor-to-liver ratio (T/L) of FAPI-Cy7-Cl increased rapidly after 2 h postinjection, reaching nearly 4.5 at 48 h, making it an optimal imaging probe for guiding TNBC surgery resection.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.